Business Wire

CA-USERTESTING

27.1.2021 03:02:09 CET | Business Wire | Press release

Share
UserTesting Launches New Test Types and Interactive Visualization Capabilities to Bring Greater Customer Insight and Intuition to Businesses

Collecting fast customer feedback has become mission-critical when competing in what is a very new and different business world. The ability to empathize with customers and understand how their buying behaviors have changed has never been more important than it is today. UserTesting , a leading provider of on-demand human insight , today announced several new capabilities designed to help companies meet the ever-evolving needs of their customers, with more test types that can give a greater understanding of how they organize and prioritize information, and interpret experiences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005448/en/

The January 2021 Product Release includes new test types for both web and mobile experiences, plus interactive visualization capabilities in the form of click maps, designed to reduce the amount of time it takes to review and analyze data.

With UserTesting’s latest release, companies can:

Understand how customers organize information and prioritize needs to deliver what they want

Card sorting helps users group, label, and describe information more effectively. UserTesting customers can now run closed, open, and hybrid card sort tests to gather insight into how to organize content and optimize their information architecture. With card sorting, companies can now more easily build experiences that put the customers’ needs first and make it easier for them to find what it is they want.

The prioritization matrix provides objective evidence to help teams prioritize tasks and projects. Not only does this reduce organizational risk by ensuring teams use customer feedback to focus on the most important tasks, but it also helps teams gain internal alignment faster with unbiased feedback directly from customers.

Leverage new test types to understand how your product, digital, and mobile iOS app experiences are resonating with customers

Developers can gather feedback on ease-of-use and perceived value before releasing apps on the App Store® online store with support for TestFlight® software public links. We’ve made it possible for you to do so with zero modifications to your project, zero lines of code, and zero configuration. Any team can easily gather qualitative feedback from real customers while they record their entire mobile screen - providing valuable input into how users interact with your app, and where you can optimize the experience.

System usability scale plus (SUS+) helps companies evaluate the usability of a product through a standardized template. This enables tracking improvements over time with longitudinal studies or easily comparing product usability to competitive products. Optional questions also allow users to measure promoter score and adjective rating.

Save time during post-test analysis with powerful and interactive visualizations

Click maps provide an interactive visual representation of all participant clicks and inputs on websites and hosted prototypes. This saves time during post-test analysis by helping companies quickly evaluate critical site interactions and then drill down further to get additional context and watch customers explain their thought process as they complete tasks and navigate sites.

"Companies are having to change and adapt at record speeds. The shift to a digital-first strategy, combined with rapidly changing consumer sentiment, has made collecting customer feedback vital to the process of designing, building, and marketing experiences,” said Kaj van de Loo, CTO at UserTesting. "Our latest offerings focus on empowering product managers, marketers, UX researchers, and designers with the tools to help them collect, prioritize, and analyze feedback so that they can build experiences that resonate with their customers, even when customer attitudes and behaviors are rapidly changing.”

Credit Notice

App Store® and TestFlight® are registered trademarks of Apple Inc.

About UserTesting

UserTesting enables every organization to deliver the best customer experience powered by human insight. With UserTesting’s on-demand Human Insight Platform , companies across industries make accurate customer-first decisions at every level, at the speed business demands. With UserTesting, product teams, marketers, digital, and customer experience executives, designers and UX researchers confidently and quickly create the right experiences for all target audiences, increasing brand loyalty and revenue. UserTesting customers including more than half of the world’s top brands. UserTesting is headquartered in San Francisco, CA. To learn more, visit www.usertesting.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release

One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye